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Background: We aimed to systematically review the efficacy of mannitol (MTL) on patients with acute severe
traumatic brain injury (TBI).
Methods: Databases such as PubMed (US National Library of Medicine), CENTRAL (The Cochrane Library 2014,
Issue 3), ISI (Web of Science: Science Citation Index Expanded), Chinese Biomedicine Database (CBM), and China
Knowledge Resource Integrated Database (CNKI) have been searched for relevant studies published between 1
January 2003 and 1 October 2014. We have established inclusion and exclusion criteria to identify RCTs, which
were suitable to be enrolled in the systematic review. The comparison group could be hypertonic saline (HS),
hydroxyethyl starch, or others. The quality assessment was based on the Cochrane Handbook for Systematic
Reviews of Interventions Version 5.0.1 and modified Jadad score scale. The major outcome was mortality, followed
by the secondary outcomes such as neurological outcome, days on intensive care unit (ICU), and ventilator day.
In addition, intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) were
used as the surrogate endpoints. Data synthesis and meta-analysis was conducted by using R (version 3.7-0.).
Results: When 176 potential relevant literatures and abstracts have been screened, four RCTs met all the inclusion criteria
and were enrolled for the meta-analysis. Amongst all the enrolled studies, two trials have provided the primary outcome
data. There was no heterogeneity between two studies (I2 = 0 %) and a fixed model was used for meta-analysis (n= 53),
pooled result indicated that the mortality was similar in mannitol intervention and control treatment, OR = 0.80, 95 % CI
[0.27, 2.37], P = 0.38. We found that both mannitol and HS were efficient in decreasing the ICP. Furthermore, the effect of
the HS on the ICP appeared to be more effective in the patients with diffuse brain injuries than mannitol did.
Conclusions: As a conclusion, the mannitol therapy cannot reduce the mortality risk of acute severe traumatic brain
injury. Current evidence does not support the mannitol as an effective treatment of acute severe traumatic brain injury.
The well-designed randomized controlled trials are in urgent need to demonstrate the adoption of mannitol to acute
severe traumatic brain injury.
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Table 1 Search terms and search strategy
Database Searched items Search strategy
PubMed 1. (Mannitol OR Mannit OR Mannite OR Osmosal OR Osmosteril OR Resectisol OR Aridol OR Bronchitol) #1 AND #2 AND #3
2. (“intracranial pressure” OR “intracranial hypotension” OR “intracranial hypertension” OR brain)
3.((randomized controlled trial[pt] OR controlled clinical trial[pt]OR (“Clinical Trials as Topic” [MeSH Major Topic]))
NOT ((“Animals” [MeSH]) NOT (“Humans” [MeSH] AND “Animals” [MeSH]))
ISI 1. Topic = (mannitol or Mannit or Mannite or Osmosal or Osmosteril or Resectisol or Aridol or Bronchitol) 1 and 2 and 3
2. Topic = (intracranial pressure OR intracranial hypotension OR intracranial hypertension OR brain*)
3. TS = (clinical OR control* OR placebo OR random OR randomised OR randomized OR randomly OR random
order OR random sequence OR random allocation OR randomly allocated OR at random)




CBM 1. “mannitol” [Full field] 2. “mannitol” [MeSH])” 3. brain injury” [Full field] 4. “Head injury” [MeSH] 5. “Parietal damage”
[Full field] 6. “Frontal damage” [Full field] 7. “Temporal damage” [Full field] 8. “Head injury” [Full field] 9. “Occipital
damage” [Full field] 10. “Brain Injury” [MeSH] 11. “intracranial hypotension” [Full field] 12. “intracranial hypotension”
[MeSH] 13. “Animal experiments” [Full field] 14. “Animal experiments” [MeSH]
(1 OR 2) AND (3 OR 4
OR 5 OR 6 OR 7 OR
8 OR 9 OR 10) AND
(11 OR 12) NOT (13 OR 14)
CNKI 1. KY = mannitol 2. KY = brain injury 3. KY = intracranial hypotension 4. KY = animals 1 AND 2 AND 3 NOT 4
Fig. 1 Literature searching and selection
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Table 2 Methodological characteristics of studies
Author Number of
patients










Single Blinded 0 Single
center
Yes 7/7
Harutjunyan et al. [50] 32 Computer
randomly
Not reported Not reported 0 Single
center
Yes 3/7




Single blinded 0 Multi-center Yes 7/7







Wang et al. Burns & Trauma  (2015) 3:8 Page 3 of 8Background
Dehydration treatment is one of the main interventions
that are adopted to prevent herniation of intracranial hyper-
tension. Mannitol is widely used in China as a dehydrating
agent in traumatic brain injury (TBI) patients with intracra-
nial hypertension. Earlier studies indicated that dehydration
therapy might decrease the intracranial pressure (ICP) of
patients with TBI by reducing cerebral edema [1]. However,
the excessive dosage of mannitol will penetrate from the
blood into the brain, where it might cause the increase of
the intracranial pressure (rebound phenomenon) and intro-
duce the secondary brain cells damage accordingly [2, 3].
Therefore, the effectiveness of the treatment of mannitol
for the intracranial hypertension in TBI is controversial [4,
5]. After the 1990s, a few new dehydration products have
been introduced as the ICP reduction mediums, such as
the hypertonic saline (HS) and the colloidal solution. Some
clinical trials have shown that the hypertonic saline is
more effective than mannitol in reducing the intracranial
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Severe neuronal damage (GCS <8). Seventeen patients
HES 200/0.5 and 15
Francony
et al. [51]
Severe brain injury (trauma, stroke); they
were aged >18 years and had sustained
elevated ICP of >20 mmHg for >10 min.
Follow up to 3 months
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catheter in 20 min
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Severe head injury (GCS <8);
follow up to 6 months
The mannitol group
20 % mannitol. The
group received 2 m
hypertonic saline. Bo
in 20 min[5, 6]. However, there are studies with various results and
conclusions [7, 8]. Single clinical trial usually has disad-
vantages by its sample size, design, or conduction. Clinical
practitioners are puzzled by the chaos of the conflicted ev-
idences and opinions to this end. The widespread use of
mannitol is in great need of clarity optimal administration.
There is uncertainty over the effectiveness of mannitol
when compared to other ICP-lowering agents and other
treatment without dehydrating agents. As a result, a sys-
tematic review is in urgent need, and this is why we
present this study.
Methods
Strategy of data retrieving
Published literatures on the use of mannitol in severe
traumatic brain injury patients were retrieved in the fol-
lowing databases: PubMed (US National Library of
Medicine), The Cochrane Library (2014, Issue 3), ISI
(Web of Science: Science Citation Index Expanded), Chinese
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groups. Mannitol if
effective than HS in CPP
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and ICP decreasing did
not differ between the
groups
Table 4 Mortality of included studies
Studies Mannitol group Control group P value
Vialet et al. [49] 5/10 (50 %) 4/10 (40 %) P >0.05
Harutjunyan et al. [50] 7/17 (41.2 %) 9/16 (56.2 %) P >0.05
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been sent to the first authors of the reports, asking
them to assist in identifying any further trials that
may have been conducted by them but not been re-
ported publicly. Eligibility was determined by reading
the reports of possible trials. The terms and strategies
of retrieving are listed in the Table 1.
Inclusion criteria
Studies evaluating adult trauma patients with severe trau-
matic brain injuries and which included mannitol as an
intervention were evaluated. The following data were re-
quired for inclusion: (1) study design: only RCTs set up
with parallel control groups were selected, excluding self-
control or crossover trials;(2) type of patients: adult trauma
patients (age ≥18 years); (3) severe brain injures (Glasgow
coma score <8) with cerebral edema. When indexes of the
two groups such as genders, ages, pre-treatment ICP, osmo-
lality levels, and Glasgow scores were matched, then the
two groups were comparable; (4) intervention: the treat-
ment group received mannitol in any dose for any duration,
while the comparison group could be placebo controlled,
different dose, different agent, or no agent; (5) reported one
or more outcomes as following: (a) primary outcome: the
mortality and (b) secondary outcome: (i) days on ICU and
(ii) ventilator day; and (6) surrogate endpoints: ICP, cerebral
perfusion pressure (CPP), and mean arterial pressure
(MAP). The mortality is related with secondary and surro-
gate outcomes, so we collect them in the study.
Exclusion criteria
The following data were required for exclusion: (1) non-
RCTs; (2) age ≤17 years, diagnosis of stroke, brain tumors,
and non-traumatic brain injuries; (3) crossover studies; (4)
did not address any primary or secondary outcomes as
mentioned above; and (5) for those studies that did notFig. 2 Comparison 1: mannitol versus hypertonic saline. Outcome 1 mortadescribe the randomization methods, we attempted to
contact the original authors. If the original authors did not
provide a response or the randomization method proved
inadequate, the articles were excluded.
Methodological quality evaluation
The methodological quality assessment table was based
on the Cochrane Reviewers’ Handbook [9] and the
modified Jadad scale [10, 11]. Data synthesis was con-
ducted by R (R package version 3.7-0.) [12]. We followed
the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) statement to report the re-
search protocol, outcome, and relevant items in this sys-
tematic review [13].
Limitations of the study
Though there are many published literatures regarding
the use of mannitol in severe traumatic brain injury pa-
tients, few of them have met the high quality standards
of evidence-based medicine. There is insufficient reliable
evidence to make suggestions on the administration of
mannitol and many unanswered questions on the opti-
mal use of mannitol in severe traumatic brain injury
patients.
Results and discussion
Study identification and selection
There were in total 176 potentially relevant titles, abstracts,
and articles that have been screened. Initial screening re-
sulted in 42 candidate studies [4, 5, 8, 14–52]. Figure 1
shows the details of the selection process and the reasons
for exclusion. There were four trails that met all inclusion
criteria and were included in the final meta-analysis. The
characteristics of these included trials are listed in Tables 2
and 3.
Major outcome: mortality
Amongst all the enrolled studies, Vialet et al. [49] and
Harutjunyan et al. [50] have provided the primary out-
come (mortality) (Table 4, Fig. 2). There is no heterogen-
eity between two studies (I2 = 0 %), and a fixed model
was used for the meta-analysis (n = 53), pooled resultlity
Table 5 ICP of included studies
Measurement of surrogate index Measurement of surrogate index
Number of episodes per day Total duration of episodes, min/day
Vialet et al. [49] Intervention: 20 % M 2 mL/Kg 13.3 ± 14.2** 95 ± 92**
Control: 7.5 % HSS 2 mL/Kg 6.8 ± 5.5** 62 ± 81**
T0 T30 T60 T90 T120
Harutjunyan et al. [50] Intervention: 15 % M 1.4 mL/Kg 23 [19–30] 12 [6–19]* 14 [7–20]*,**
Control: 7.2 % NaCl/HES 1.8 mL/Kg 22 [19–31] 10 [6–14]* 11 [5–18]
Cottenceau et al. [52] Intervention: 20 % M 4 mL/Kg 16.3 ± 9.3 10.5 ± 6.8* 13.6 ± 7.5*
Control: 7.5 % HSS 2 mL/Kg 17.9 ± 9.9 13.9 ± 7.8* 13.9 ± 7.8*
Δ% Δ% Δ% Δ% Δ%
Francony et al. [51] Intervention: 20 % M 231 mL 31 ± 6 −41 ± 23* −45 ± 19* −35 ± 12* −32 ± 12*
Control: 7.45 % HSS 100 mL 27 ± 3 −37 ± 18* −35 ± 14* −31 ± 15* −23 ± 10*
*P <0.05 vs. T0; **P < 0.05 vs. mannitol
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intervention and control treatment, OR = 0.80, 95 % CI
[0, 27, 2.37], P = 0.38.
Secondary outcomes
In terms of the report of the secondary outcomes and sur-
rogate endpoints, four RCTs were not uniformed and the
data synthesis was not available. Hence, we have conducted
a qualitative analysis afterward. There was no difference be-
tween two groups in neurological outcome (Glasgow out-
come scale (GOS) 5/10 vs. 6/10; P >0.05) and days on ICU




Mannitol therapy may have a detrimental effect on de-
crease ICP when compared to hypertonic saline therapy.
Vialet et al. [49] compared 20 % mannitol group withTable 6 CPP of included studies
Measuremen
Number of e
Vialet et al. [49] Intervention: 20 % M 2 mL/Kg 3.1 ± 3.6**
Control: 7.5 % HSS 2 mL/Kg 4.0 ± 4.6**
T0
Harutjunyan et al. [50] Intervention: 15 % M 1.4 mL/Kg 61 [47–71]
Control: 7.2 % NaCl/HES 1.8 mL/Kg 60 [39–78]
Cottenceau et al. [52] Intervention: 20 % M 4 mL/Kg 72.1 ± 12.8
Control: 7.5 % HSS 2 mL/Kg 72.8 ± 15.1
Δ%
Francony et al. [51] Intervention: 20 % M 231 mL 75 ± 15
Control: 7.45 % HSS 100 mL 81 ± 12
*P <0.05 vs. T0; **P <0.05 vs. mannitol7.5 % HS group. The result suggested that the mean
number (13.3 ± 14.6 vs. 6.9 ± 5.6 episodes) of intracranial
hypertension episodes (ICP >25 mmHg) per day and the
daily duration (131 ± 123 vs. 67 ± 85 min) of intracranial
hypertension episodes were significantly higher in the
mannitol group (P <0.01) than those in the HS group [49].
The rate of clinical failure was also significantly higher in
the mannitol group (7 of 10 vs. 1 of 10 patients; P <0.01)
than that in the HS group [49]. Harutjunyan et al. [50]
compared 15 % mannitol to 7.2 % hypertonic saline
hydroxyethyl starch 200/0.5 (7.2 % NaCl/HES 200/0.5).
NaCl/HES 200/0.5 (7.2 %) caused a greater decrease in
the ICP than mannitol did (57 vs. 48 %; P <0.01) [50]. Both
groups decreased the ICP to below 15 mmHg; but the
mean time was significantly longer in the mannitol
group (8.7 vs. 6 min; P <0.01) than that in the HS
group. Francony et al. [51] and Cottenceau et al. [52]
have shown that the spectrum of the ICP decrease
was significantly larger in the HS group than in thet of surrogate index Measurement of surrogate index
pisodes per day Total duration of episodes, min/day
62 ± 107**
58 ± 83**
T30 T60 T90 T120
72 [60–93]* 73 [58–88]*,**
75 [62–86]*,** 69 [56–89]*
76.9 ± 17.48 74.7 ± 13.3*
79.3 ± 11.6* 74.3 ± 13.1*
Δ% Δ% Δ% Δ%
+21 ± 23* +22 ± 21* +14 ± 15* +17 ± 14*
+21 ± 23* +9 ± 10* +8 ± 11* +7 ± 6*
Table 7 MAP of included studies
T0 T30 T60 T90 T120
Harutjunyan et al. [50] Intervention: 15 % M 1.4 mL/Kg 84 [68–92] 81 [69–106] 82 [68–108]
Control: 7.2 % NaCl/HES 1.8 mL/Kg 84 [64–98] 85 [74–100]*,** 84 [63–94]*
Cottenceau et al. [52] Intervention: 20 %M 4 mL/Kg 87.6 ± 12.2 87.4 ± 11.6 87.9 ± 10.9
Control: 7.5 % HSS 2 mL/Kg 90.6 ± 12.6 91.2 ± 10 87.2 ± 10.5
Δ% Δ% Δ% Δ% Δ%
Francony et al. [51] Intervention: 20 % M 231 mL 106 ± 16 +2 ± 9 +1 ± 10 0 ± 10* +2 ± 7
Control: 7.45 %Hss 100 mL 108 ± 13 −5 ± 7 −2 ± 7 −3 ± 7* −1 ± 5
*P <0.05 vs. T0; **P <0.05 vs. mannitol
Wang et al. Burns & Trauma  (2015) 3:8 Page 6 of 8mannitol group, and the spectrum was about 10 %
over the entire stage. The changes of ICP across the
four studies are summarized in Table 5.
CPP
Mannitol therapy may have a small detrimental effect in in-
creasing CCP when compared to hypertonic saline therapy.
Mannitol therapy may only have a beneficial effect in im-
proving the blood supply of local brain tissue. Vialet et al.
[49] has indicated that there was no significant difference in
the mean number (3.1 ± 3.6 vs. 4.0 ± 4.6 episodes) of cere-
bral perfusion hypotension episodes (CPP <70 mmHg) per
day and the daily duration (62 ± 107 vs. 52 ± 83 min) of
cerebral perfusion hypotension episodes between the two
groups (P >0.05) [49]. Harutjunyan et al. [50] has shown
that the CPP had significantly sharp increase in both groups
after the start of the infusion (P <0.0001), and the HS group
was significantly higher than the mannitol group at 30 min
after the beginning of the infusion (P <0.05) [50]. The max-
imum increase occurred at 30 min after the beginning of
the infusion in both groups, and the HS group increased
more than the mannitol group did (27 vs. 18 %; P <0.05)
[50]. Francony et al. [51] suggested that mannitol could
only effectively improve the CPP and the blood supply of
the local brain tissue [51]. Cottenceau et al. [52] suggested
that the maximum of CPP increase occurred at 30 minTable 8 Plasma osmolality and serum sodium of included studies
Measurement of surrogate index
Vialet et al. [49] Serum sodium (Δ%)
Francony et al. [51] Serum sodium (Δ%)
Urine output (mL/h)
Harutjunyan et al. [50] Serum sodium
Plasma
Osmolality
Cottenceau et al. [52] Serum sodium
*P <0.05 vs. T0; **P <0.05 vs. mannitolafter the beginning of the infusion in both groups, but there
was no significantly difference between the 20 % mannitol
and the 7.5 % HS group [52]. The changes of CCP across
the four studies are summarized in Table 6.
MAP
Mannitol therapy may have no beneficial effect in in-
creasing MAP when compared to hypertonic saline ther-
apy. Harutjunyan et al. [50] shown that MAP had a
significantly sharp increase in 15 % mannitol and 7.2 %
NaCl/HES 200/0.5 after the beginning of the infusion (P
<0.05). There was no significant difference in the in-
crease of MAP between two groups (5.8 vs. 7.6 %), but
the maximum increase occurred significantly shorter in
the mannitol group than in the HS group (10 vs.
30 min) [50]. Francony et al. [51] and Cottenceau et al.
[52] have shown in their research that there was no sig-
nificant difference in MAP between the 20 % mannitol
and the 7.5 % HS. The changes of MAP across the four
studies are summarized in Table 7.
Plasma osmolality, urine, and serum sodium
Mannitol therapy may have no difference in elevating the
plasma osmolality and serum sodium when compared to
hypertonic saline therapy. Mannitol therapy may have a
small beneficial effect in increasing the urine output. ButIntervention Control
+1.3 ± 10.1* +4.7 ± 8.2*
−1.7 ± 3.2** +2.1 ± 1.4**
306 ± 174** 114 ± 72**
T0 143 (136–148)
T30 148 (144–153)*
T0 286 (270–315)* 284 (273–300)*
T30 295 (278–327)* 300 (284–319)*
T0 141.3 ± 5.1 144.2 ± 5.1
T30 139.1 ± 4.1*,** 148.3 ± 5.2*,**
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et al. [49] suggested that the plasma osmolality and serum
sodium elevated significantly in both the 20 % mannitol
group and the 7.5 % HS group after the beginning of the
infusion (P <0.05), but there was no significant difference
between the two groups. Harutjunyan et al. [50] showed
the serum sodium increased in both the 15 % mannitol
and the 7.2 % NaCl/HES 200/0.5 (P <0.05), although there
was no significant difference between the two groups.
Francony et al. suggested that mannitol caused a signifi-
cantly greater increase in urine output (P 0.05) than HS
[51]. Cottenceau et al. suggested that the HS caused a sig-
nificantly greater increase of serum sodium (P = 0.0000),
although mannitol caused a significantly decrease of it
(P = 0.0000) [52]. The changes of plasma osmolality and
sodium across the four studies are summarized in Table 8.
Conclusions
Published literatures regarding the use of mannitol in severe
traumatic brain injury patients have rarely met the high
quality standards of evidence-based medicine. This system-
atic review has revealed that the mannitol therapy cannot
reduce death risk for TBI patients suffering from raised ICP.
Four RCTs retrieved by this study which have found
reduced intracranial pressure (ICP): two RCTs suggested
that hypertonic saline was superior to mannitol, and the
time of maximized effect was earlier than that of manni-
tol; whilst the other two RCTs have proposed mannitol
was equally on the impact of ICP comparing with hyper-
tonic saline. In the elevation of CPP and MAP, one RCT
found that hypertonic saline was superior to mannitol,
whilst the other three RCTs considered no significant
difference between the two agents. One RCT showed
that mannitol might have a beneficial effect on cerebral
hemodynamic when compare to hypertonic saline. How-
ever, some domestic studies have shown that the 23.4 %
HS have faster and longer effect than the 20 % mannitol
did in the treatment of raised ICP of severe brain injury
[53–56]. Thus, the points of those researchers on this
issue are varied and contradicted with each other.
Currently, mannitol is widely used as a part of conven-
tional therapy of the TBI patients who suffer from intracra-
nial pressure hypertension. Based on the most credible
evidence from this study, mannitol therapy cannot reduce
the mortality risk in this type of patients. Well-designed
randomized controlled trials are urgently needed to demon-
strate the efficacy of mannitol to acute severe traumatic
brain injury.
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